Polymyalgia Rheumatica and Giant Cell Arteritis

William P. Docken MD:

For whatever it’s worth, in such a patient, I currently do not routinely deploy low-dose aspririn or pneumocystis pneumonia prophylaxis, as I am unpersuaded as to their value by either the published studies or clinical experience, but I do aggressively use bisphosphonates, which, despite their recently tarnished reputation, have been of clear value in decreasing fracture risk from CS.

An easy but informative read on PMR and GCA with some nice references to read through as well.